Quince Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
CONDENSED CONSOLIDATED STAT EMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development | $5,461 | $6,553 | $12,306 | $14,698 |
| Acquired in-process research and development | 59,000 | — | 59,000 | — |
| General and administrative | 16,626 | 3,342 | 20,893 | 8,131 |
| Gain on Orphai Acquisition | (1,305) | — | (1,305) | — |
| Intangible asset impairment charge | — | — | 67,808 | — |
| Fair value adjustment for contingent consideration | — | 532 | (64,330) | 2,456 |
| Total operating expenses | 79,782 | 10,427 | 94,372 | 25,285 |
| Loss from operations | (79,782) | (10,427) | (94,372) | (25,285) |
| Fair value adjustment for debt | — | (501) | 12,168 | (945) |
| Fair value adjustment for warrants | 4,507 | (4,464) | 35,623 | (4,464) |
| Warrant issuance costs | (874) | (872) | (874) | (872) |
| Interest income | 584 | 311 | 744 | 717 |
| Other (expense) income, net | 152 | (29) | 1,871 | (116) |
| Net loss before income tax expense | (75,413) | (15,982) | (44,840) | (30,965) |
| Income tax benefit (expense) | (75) | (67) | 5,264 | (114) |
| Net loss | (75,488) | (16,049) | (39,576) | (31,079) |
| Other comprehensive loss: | ||||
| Foreign currency translation adjustments | (355) | 4,216 | (1,490) | 6,261 |
| Unrealized loss on available-for-sale securities | — | (17) | (5) | (70) |
| Total comprehensive loss | $(75,843) | $(11,850) | $(41,071) | $(24,888) |
| Net loss per share – basic and diluted (1) | $(12.31) | $(68.75) | $(12.01) | $(137.17) |
| Weighted average shares of common stock and in-substance common stock outstanding – basic and diluted (1) | 6,132,845 | 233,431 | 3,295,727 | 226,571 |
(1) Adjusted prior period net loss per share and weighted average of common shares outstanding to reflect the 1-for-10 reverse stock split effected on April 10, 2026 and the 1-for-20 reverse stock split effected on June 29, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.